P71 S100A14 as a diagnostic marker for hepatocellular carcinoma among Sudanese patients at Ibn Sina hospital

Abstract

<h3>Background</h3> Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. HCC is with high morbidity and mortality rates especially in patients with late present. Early detection and diagnosis represent the major concern in the management of HCC. S100A14 biomarker has been recently used in the diagnosis of HCC. <h3>Objective</h3> This study aimed at evaluating S100A14 as a diagnostic marker for HCC among Sudanese patients. <h3>Methods</h3> This was a case control study conducted in Ibn Sina hospital. It included 89 patients, 30 with HCC, 30 with liver cirrhosis and 29 control patients. Five ml of whole blood were taken from participants. Then, S100A14 and serum alpha fetoprotein was investigated using ELISA technique. Data analyzed using SPSS version 25. <h3>Results</h3> The participants gender ratio was M:F 3.4:1.05 S100A14 was significantly elevated in the HCC group. A pairwise comparison revealed that there was significant difference between Cirrhosis group and control group, HCC group and control group. However, there was no significant relationship between HCC group and cirrhosis group. The Roc curve for serum S100A14 between HCC and control group is with AUC 0.695, a sensitivity of 83% and specificity of 49.6% at cut-off value ≥5.012, figure (1). The ROC curve of alpha-fetoprotein in HCC group and cirrhosis group the sensitivity was 76% and the specificity was 44% at the cut-off point of ≥ 5.800 ng/ml with an area under the curve (AUC) of 0.770, figure (1). <h3>Conclusion</h3> The results considered that S100A14 had high sensitivity and low specificity.